-
Posted by
Two Blokes Jul 28 -
Filed in
Stock
-
1 view
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market confidence, investors and analysts say.
